Author

R. Vander Velde

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:statistical model· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Approach:diffusion model· 1

Frequent Co-Authors

A. Marusyk· 4 shared A. C. Tan· 2 shared B. Desai· 2 shared J. Scott· 2 shared N. Yoon· 2 shared A. Dhawan· 1 shared A. Durmaz· 1 shared A. R. A. Anderson· 1 shared

Activity by Year

2018-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. Marusyk

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Antifragile therapy

J. West, B. Desai, M. Strobl, L. Pierik, R. Vander Velde, C. Armagost, R. Miles, M. Robertson-Tessi, A. Marusyk, A. R. A. Anderson

This paper introduces a mathematical framework to quantify cancer cell line fragility or antifragility to treatment variability and applies it to treatment resistance and collateral sensitivity.

bioRxiv · Oct 8, 2020 · PreprintCancer Biology

Spontaneous Cell Fusions as a Mechanism of Parasexual Recombination in Tumor Cell Populations

D. Miroshnychenko, E. Baratchart, M. Ferrall-Fairbanks, R. Vander Velde, M. A. Laurie, M. Bui, A. C. Tan, P. M. Altrock, D. Basanta, A. Marusyk

This study investigates spontaneous cell fusions in tumor cell populations as a mechanism of parasexual recombination, finding evidence of low-frequency fusions and their role in increasing clonal heterogeneity.

bioRxiv · Mar 9, 2020Cancer Biology

Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures

R. Vander Velde, N. Yoon, V. Marusyk, A. Durmaz, A. Dhawan, D. Myroshnychenko, D. Peral, B. Desai, O. Balynska, J. Poleszhuk, K. Liu, M. Abazeed, A. C. Tan, O. Mian, E. Haura, , A. Marusyk

The paper investigates resistance to ALK inhibitors in NSCLC, finding that resistance develops through gradual, multifactorial genetic and epigenetic changes rather than single mutations or reprogramming.

bioRxiv · Nov 19, 2019Cancer Biology

Optimal Therapy Scheduling Based on a Pair of Collaterally Sensitive Drugs

N. Yoon, R. Vander Velde, A. Marusyk, J. Scott

This paper develops a dynamical model to determine optimal drug switching schedules for collaterally sensitive drugs in cancer treatment, finding that the initial drug phase should be shorter than its effective duration.

bioRxiv · Feb 20, 2018Cancer Biology